Active, not recruitingPhase 2NCT04740476
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Studying Dravet syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stoke Therapeutics, Inc
- Principal Investigator
- Ann Dandurand, MDMedical Director
- Intervention
- zorevunersen (STK-001)(drug)
- Enrollment
- 60 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2029
Study locations (17)
- University of California San Francisco Medical Center, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Florida Hospital for Children, Orlando, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Iowa Children's Hospital, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Michigan Medicine, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- NYU Comprehensive Epilepsy Center, New York, New York, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT LeBonheur Pediatric Specialists, Inc., Memphis, Tennessee, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04740476 on ClinicalTrials.govOther trials for Dravet syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07251673Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc
- RECRUITINGPHASE4NCT06598449Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Longboard Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE3NCT06118255A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeUCB BIOSCIENCES, Inc.
- RECRUITINGPHASE1, PHASE2NCT05419492A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06283212A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Encoded Therapeutics